Proclara Biosciences
Pioneering therapies to combat neurodegenerative diseases with innovative protein disaggregation technology.
General Information
Get notified when Proclara Biosciences moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Proclara Biosciences
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About Proclara Biosciences
Taxonomy: neurodegenerative diseases, protein disaggregation, drug development, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, therapeutics, preclinical research, neuropharmacology, innovation, biopharmaceuticals, Cambridge, Massachusetts
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | - | 09 Nov 2018 | |
| Series E | •••••• | - | 07 Sep 2016 | |
| Series D | •••••• | - | 14 Jan 2015 | |
| Series D | •••••• | 2 |
|
25 Mar 2014 |
| Series C | •••••• | 2 |
|
06 May 2013 |
Proclara Biosciences Alternatives & Competitors
-logo.jpg "Kineta (Reverse Merger With Yumanity Therapeutics)"){kind=logo}
Pioneering new horizons in neurodegenerative disease treatment by addressing protein misfolding.
Precision therapeutics for protein misfolding disorders, including Alzheimer's, ALS and Parkinson’s...
Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spi...
FAQ About Proclara Biosciences
Don't just browse. Track.
Signal Tracker monitors Proclara Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.